Ultragenyx Pharmaceutical (RARE) News
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.48+0.19 (+1.24%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RARE news summary
We found 3 recent headlines mentioning Ultragenyx Pharmaceutical (RARE): 1 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, RARE is up 1.24% at $15.48. The most recent story, "Stocks Settle Lower on Higher Bond Yields", was published by Nasdaq on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Ultragenyx Pharmaceutical headlines
- Stocks Settle Lower on Higher Bond YieldsThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.22% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down…NasdaqMSTR, DE, RARE, ADI
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB